Drug Trial Radar · NCT04974138
China Stroke Primary Prevention Trial 2 for Participants With H-type Hypertension and MTHFR 677 CC/CT Genotype (CSPPT2-CC/CT)
Last checked: Nov 19, 2026Latest source record: Feb 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
32,000
Planned (sponsor's estimate)
Start
Aug 22, 2024
Primary completion
Jun 30, 2030
Study completion Jun 30, 2030
Sponsor
- Lead sponsor
- Shenzhen Ausa Pharmed Co.,LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Peking University First Hospital; Second Affiliated Hospital of Nanchang University; The First People's Hospital of Lianyungang; The Affiliated Hospital Of Guizhou Medical University; Lianyungang Oriental Hospital; Tengzhou Central People's Hospital; The First Affiliated Hospital of Bengbu Medical University; Shenzhen Prospective Medical Technology Co., LTD; Weinan Central Hospital; The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine; Loudi Central Hospital; Yancheng First People's Hospital; TAIHE country people's hospital; First Affiliated Hospital of Gannan Medical University; Yangjiang People's Hospital; Deyang People's Hospital; Bozhou people's hospital; Lianyungang Second People's Hospital; The Affiliated Hospital Of Southwest Medical University; Chengdu Fifth People's Hospital; Chizhou people's hospital
- First posted
- Jul 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 45 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, randomized, double-blind, double-dummy, controlled clinical trial. This trial will include 32,000 Chinese men and women with hypertension (H-type hypertension), MTHFR 677 CC or CT genotype, elevated plasma total homocysteine (tHcy ≥10µmol/L), and insufficient serum folate levels (\<12ng/mL). The participants will be first stratified by their MTHFR 677 genotype (CC vs. CT), then randomized to one of two treatment groups in a 1:1 ratio. Group A: amlodipine tablet (5mg), taken orally, once daily, serving as active comparator. Group B: amlodipine folic acid 5.8mg tablet (5mg amlodipine and 0.8mg folic acid), taken orally, once daily. The treatment period is five years and primary endpoint is first ischemic stroke.
Conditions
- Hypertension
- MTHFR 677 CC or CT Genotype
- Elevated Plasma Homocysteine (Hcy≥10µmol/L)
- Insufficient Plasma Folate Levels (<12ng/mL)
Interventions
Amlodipine besylateDrug
The amlodipine used in this study is a listed product. Amlodipine tablets and amlodipine folic acid (dummy) are provided in aluminum-plastic blisters packaging. Each package includes 100 days of treatment drug (including 10 extra days of treatment for the follow-up window). A package of medication consists of 20 plates, each plate includes a total of 10 tablets arranged as follows: amlodipine 5mg/tablet x5 tablets + amlodipine-folic acid (dummy) x5 tablets. Affixed to the medication package is the randomized treatment drug label (200 tablets/package, 2 tablets/day).
Amlodipine besylate and folic acidDrug
The amlodipine besylate and folic acid tablets have been approved for listing by the China Food and Drug Administration, approval number: Zhunzi H20180020. Amlodipine-folic acid tablets and amlodipine (dummy) are provided in aluminum-plastic blisters packaging. Each package includes 100 days of treatment drug (including 10 extra days of treatment for the follow-up window). A package of medication consists of 20 plates, each plate includes a total of 10 tablets arranged as follows: amlodipine-folic acid 5.8mg x5 tablets + amlodipine (dummy) x5 tablets. Affixed to the medication package is the randomized treatment drug label (200 tablets/package, 2 tablets/day).
Amlodipine placebosDrug
An amlodipine placebo is a dummy pill of an amlodipine tablet with an identical appearance.
Amlodipine-folic acid placebosDrug
An Amlodipine folic acid placebo is a dummy pill of an amlodipine folic acid tablet with an identical appearance.
Primary outcomes
What the sponsor says the trial is designed to measure.
- First ischemic strokeTime frame: By the end of the fifth year from baseline
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
First Affiliated Hospital of Bengbu Medical University
Bengbu, Anhui, China · Not yet recruiting
Bozhou
Bozhou, Anhui, China · Not yet recruiting
Chizhou People's Hospital
Chizhou, Anhui, China · Not yet recruiting
Taihe County People's Hospital
Fuyang, Anhui, China · Not yet recruiting
Peking University First Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
Yangjiang People's Hospital
Yangjiang, Guangdong, China · Not yet recruiting
The Affiliated Hospital Of Guizhou Medical University
Guiyang, Guizhou, China · Not yet recruiting
The First Affiliated Hospital of Hunan University of Medicine
Huaihua, Hunan, China · Not yet recruiting
Loudi Central Hospital
Loudi, Hunan, China · Not yet recruiting
Lianyungang Oriental Hospital
Lianyungang, Jiangsu, China · Recruiting
The First People's Hospital of Lianyungang
Lianyungang, Jiangsu, China · Not yet recruiting
The Second People's Hospital of Lianyungang
Lianyungang, Jiangsu, China · Not yet recruiting
Yancheng First People's Hospital
Yancheng, Jiangsu, China · Not yet recruiting
The First Affiliated Hospital of Gannan Medical University,
Ganzhou, Jiangxi, China · Not yet recruiting
Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China · Not yet recruiting
Weinan Central Hospital
Weinan, Shaanxi, China · Not yet recruiting
Tengzhou Central People's Hospital
Zaozhuang, Shandong, China · Not yet recruiting
Chengdu Fifth People's Hospital
Chengdu, Sichuan, China · Not yet recruiting
Deyang People's Hospital
Deyang, Sichuan, China · Not yet recruiting
The Affiliated Hospital of Southwest Medical University
Luzhou, Sichuan, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.